

Radiology Reimbursement Information

Setting: Freestanding/Independent Diagnostic Testing Facility (IDTF)

About DOTAREM[®]:

DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.¹

IMPORTANT SAFETY INFORMATION¹

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- The risk for NSF appears highest among patients with:
 - Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
 - Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Important Safety Information continued onto the following pages.

Billing for DOTAREM:

DOTAREM (gadoterate meglumine), having received FDA approval for use in magnetic resonance imaging (MRI) of the brain, spine and associated tissues in adult and pediatric patients (including term neonates), has recently been assigned a distinct Healthcare Common Procedural Coding System (HCPCS) code, A9575, by the Centers for Medicare and Medicaid Services (CMS). A9575 should be used for all billing to all third-party payers, governmental and private in all patient settings. This code, effective January 1, 2014, was made available to all Medicare Administrative Contractors (MACs) and all major national and significant regional payers.

DOTAREM[®]

(gadoterate meglumine) Injection

Setting: Freestanding/Independent Diagnostic Testing Facility (IDTF)

A9575 (HCPCS Code)*:

In order for payers to correctly reimburse HCPCS A9575 (Injection, gadoterate meglumine, 0.1 ml), providers must indicate the following in the electronic narrative (Item 24 or the descriptor field) of the CMS 1500 form:

- The name of the drug
- National Drug Code (NDC) number
- The total dosage (plus strength of dosage, if appropriate)
- The method of administration
- NDC unit of measure is mL

NOTE: This is a requirement of HIPAA 5010 – actual units billed in the line item with A9575 should be the amount times ten to account for the HCPCS descriptor being 0.1 mL.

2 mL = 20 units

7.5 mL = 75 units

15 mL = 150 units

20 mL = 200 units

NOTE: As of January 1st, 2017, CMS requires the waste from a single use vial be reported with the –JW modifier (drug amount discarded/not administered to any patient). Providers must bill the amount administered with A9575 and then bill waste from a single use vial with A9575-JW.

Medicare:

All contrast agents, including those utilized in MRI procedures, are paid separately by Medicare in the Medicare Physician Fee Schedule (MPFS) setting. Reimbursement will be based on Average Sales Price (ASP) updated on a quarterly basis by the Centers for Medicare and Medicaid Services (CMS).

Private/Commercial Payers:

Contrast reimbursement may be paid separately when billed with a procedure. This varies from payer to payer. Providers, please check your contracts and/or contact private payers for further information, or call the DOTAREM[®] Reimbursement Support line.

For assistance, please contact DOTAREM Reimbursement Support at 1-855-368-2736, Monday–Friday, 7 am–7 pm ET.

*Reimbursement information provided is for illustrative purposes only and does not constitute legal advice. Information provided is gathered from third party sources and is subject to change without notice due to frequently changing laws, rules and regulations. Guerbet makes no guarantee that the use of this information will prevent differences of opinion or disputes with Medicare or other third party payers as to the correct form of billing or the amount that will be paid to providers of service. The provider of service has the responsibility to determine medical necessity and to submit appropriate codes and charges for care provided. Please contact your local payers, reimbursement specialists and/or legal counsel for interpretation of coding, coverage, and payment policies. Guerbet does not promote the use of its products outside FDA-approved labeling.

For more information on Dotarem, please see Full Prescribing Information including Boxed Warning and Medication Guide.

IMPORTANT SAFETY INFORMATION¹

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

- The risk for NSF appears highest among patients with:
 - Chronic, severe kidney disease (GFR < 30 mL/min/1.73m²), or
 - Acute kidney injury.
- Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
- For patients at highest risk for NSF, do not exceed the recommended DOTAREM dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

INDICATIONS AND USAGE

DOTAREM[®] (gadoterate meglumine) injection is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

CONTRAINDICATIONS

History of clinically important hypersensitivity reactions to DOTAREM.

WARNINGS AND PRECAUTIONS

- Hypersensitivity Reactions: Anaphylactic and anaphylactoid reactions have been reported with DOTAREM, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died. In most cases, initial symptoms occurred within minutes of DOTAREM administration and resolved with prompt emergency treatment.
- Before DOTAREM administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to DOTAREM.
- Administer DOTAREM only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, including personnel trained in resuscitation.
- Gadolinium Retention: Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by brain, skin, kidney, liver and spleen. The duration of retention also varies by tissue, and is longest in bone. Linear GBCAs cause more retention than macrocyclic GBCAs.
- Consequences of gadolinium retention in the brain have not been established. Adverse events involving multiple organ systems have been reported in patients with normal renal function without an established causal link to gadolinium retention.
- Acute Kidney Injury: In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.

- Extravasation and Injection Site Reactions: Ensure catheter and venous patency before the injection of DOTAREM. Extravasation into tissues during DOTAREM administration may result in tissue irritation.

ADVERSE REACTIONS

- The most common adverse reactions associated with DOTAREM in clinical trials were nausea, headache, injection site pain, injection site coldness and rash.
- Serious adverse reactions in the Postmarketing experience have been reported with DOTAREM. These serious adverse reactions include but are not limited to: arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

USE IN SPECIFIC POPULATIONS

- **Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. The human data on the association between GBCAs and adverse fetal outcomes are limited and inconclusive. Advise pregnant women of the potential risk of fetal exposure to GBCAs.
- **Lactation:** There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
- **Pediatric Use:** The safety and efficacy of DOTAREM at a single dose of 0.1 mmol/kg has been established in pediatric patients from birth (term neonates \geq 37 weeks gestational age) to 17 years of age based on clinical data. The safety of DOTAREM has not been established in preterm neonates. No cases of NSF associated with DOTAREM or any other GBCA have been identified in pediatric patients age 6 years and younger.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see the full Prescribing Information, including the patient Medication Guide, for additional important safety information.

References: 1. Dotarem [package insert]. Princeton, NJ: Guerbet LLC; Apr 2018.

GU07181130F

